ERBB2 and gastric cancer: In 2013, at the ASCO annual meeting, researchers reported a phase III, randomized, double-blind trial evaluating the efficacy and safety of CapeOx in combination with lapatinib (CapeOx+L) or placebo (CapeOx+P) as a first-line treatment for advanced or metastatic HER2-positive gastric cancer patients (LOGiC Trial) [11].